Isomorphic Labs, the Alphabet-owned drug discovery spinout led by Nobel laureate Demis Hassabis, is in early talks to raise new funding at a valuation of $40 billion to $50 billion, Bloomberg reported on October 8, citing people familiar with the matter. The potential round would come less than five months after the company closed a $2.1 billion raise, and it would roughly double the valuation it carried at that time. No terms have been finalized, and the people cautioned the talks could still fall apart before any deal is signed.
From DeepMind Spinout to Drug Designer
Isomorphic Labs was spun out of Google DeepMind in 2021 to apply the protein-folding techniques behind AlphaFold to the much harder problem of designing new medicines. Hassabis, who shared the 2024 Nobel Prize in Chemistry for AlphaFold, has positioned the company as a bet that AI can compress the drug discovery timeline from years to months by predicting how candidate molecules will bind to disease targets before a single compound is synthesized in a lab. The company has struck research partnerships with Eli Lilly and Novartis worth more than $3 billion combined in milestone payments since 2023. Those deals typically pay Isomorphic incrementally as its AI-designed candidates clear successive stages of preclinical validation, meaning the bulk of the headline figures remains contingent on scientific results rather than guaranteed revenue, a structure common across the AI-drug-discovery sector that makes any single company’s announced deal value difficult to compare directly against another’s cash-in-hand.
A Slipping Timeline for Clinical Proof
The valuation jump arrives alongside a more cautious signal from Hassabis himself: he now expects Isomorphic’s first clinical trials to begin by the end of 2026, a year later than the timeline he had previously floated. The delay underscores a gap that has dogged the entire AI-drug-discovery field: software can generate and rank candidate molecules quickly, but getting a single compound through toxicology screening, manufacturing, and a regulatory-cleared trial application still takes years, regardless of how fast the design phase moves.
Money Is Chasing the Sector Despite No Approvals Yet
Isomorphic’s reported talks land in a week of heavy AI-biotech dealmaking. Insilico Medicine dosed its first patient in what it calls the first Phase III trial of a drug whose target and molecule both originated in generative-AI software, and Chai Discovery signed its sixth pharma partnership in nine months with GSK. Yet no AI-discovered drug has reached FDA approval, according to industry trackers, which means investors are pricing platforms on the promise of faster discovery rather than on any proven, approved product.
Skeptics Point to the Sample-Size Problem
Insilico’s own lead investigator offered a telling caveat about the Phase III trial now underway, noting that the sample size in each patient group was relatively limited — a reminder that even the furthest-along AI-designed drug candidates are being tested on a small scale before any claim of clinical benefit can be made. Critics of the AI-drug-discovery boom argue that the industry’s narrative has outpaced its evidence, since most of the public claims about faster discovery times are self-reported by the companies raising money on those claims, not independently audited.
Believers See a Software Moat in Biology
Supporters counter that Isomorphic’s backing from Alphabet gives it computing resources and a tie to AlphaFold’s structural-biology database that smaller rivals cannot match, and that pharma giants like Lilly and Novartis would not have committed billions in milestone payments without seeing internal validation of the platform’s hit rates. They frame the higher valuation as a bet on compounding advantage: every drug program the company runs generates more training data for the next one, in theory narrowing the gap between software prediction and biological reality over time.
What Comes Next
If the round closes near the reported range, Isomorphic would become one of the most richly valued private AI companies outside the large language model labs, and the pressure to show clinical results will only intensify. Hassabis’s own revised end-of-2026 target for a first human trial gives the company roughly a year to convert its funding and partnerships into the kind of data that would validate — or puncture — the valuation now being discussed. Investors weighing a stake at this price will also be watching how Isomorphic’s results compare with Insilico’s ongoing Phase III trial, since a disappointing readout from any AI-originated drug candidate, regardless of which company produced it, could chill enthusiasm for the entire category and make the reported $40-50 billion figure look premature in hindsight.
Photo: Mikhail Nilov / PEXELS via Pexels
